<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016430</url>
  </required_header>
  <id_info>
    <org_study_id>13-863</org_study_id>
    <nct_id>NCT02016430</nct_id>
  </id_info>
  <brief_title>Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)</brief_title>
  <acronym>GRADY</acronym>
  <official_title>Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our group has recently identified the association between gut-flora-mediated carnitine and
      phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and
      cardiovascular risk. This study investigates the ability for dietary intervention to modulate
      TMAO levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot human study to characterize the relationship between gut flora-associated
      TMAO generation and dietary intervention. The investigators hypothesize that tailored dietary
      interventions may help to reduce the ability for gut flora to generate TMAO in individuals
      with elevated TMAO levels. Specific aims include:

        1. To investigate the proportion of subjects with persistently elevated circulating TMAO
           levels.

        2. To compare the amount of TMAO generated from gut flora using stable-isotope-labelled
           choline, carnitine, and betaine in subjects with elevated versus normal circulating TMAO
           levels.

        3. To evaluate the effect of dietary interventions on the amount of TMAO generated from gut
           flora using stable-isotope-labelled choline, carnitine, and betaine in subjects with
           elevated circulating TMAO levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TMAO level</measure>
    <time_frame>From baseline to 12 weeks follow-up</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dietary Modification</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>MeLT Dietary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mediterranean Low-TMAO (MeLT) diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLC Dietary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic Lifestyle Changes (TLC) diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MeLT dietary intervention with TMAO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mediterranean Low TMAO diet with TMAO levels reported</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MeLT Dietary intervention</intervention_name>
    <description>Mediterranean diet containing food with low TMAO content.</description>
    <arm_group_label>MeLT Dietary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TLC Dietary intervention</intervention_name>
    <description>Standard American Heart Association (AHA) recommendations for dietary counseling</description>
    <arm_group_label>TLC Dietary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MeLT dietary intervention with TMAO</intervention_name>
    <description>Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.</description>
    <arm_group_label>MeLT dietary intervention with TMAO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age 18 years or above.

          -  Elevated TMAO metabolizers (&gt;5 ÂµM) based on screening test.

          -  Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week
             prior to starting study and staying on the same aspirin regimen during the duration of
             the 12-week study.

          -  Willing to sign consent form or to follow study protocol, which includes 12-week
             dietary modification.

        Exclusion Criteria:

          -  Significant chronic illness or end-organ dysfunction, including known history of
             uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases.

          -  Active infection or received antibiotics within 2 months of study enrollment

          -  Use of over-the-counter probiotic within past month, or ingestion of yogurt within
             past 7 days

          -  Having undergone bariatric procedures or surgeries such as gastric banding or bypass.

          -  Pregnancy.

          -  Any condition which, in the judgment of the Investigator, would place a patient at
             undue risk by being enrolled in the trial, or cause inability to comply with the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. H. Wilson Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanley L. Hazen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Engelman</last_name>
    <phone>216-636-6153</phone>
    <email>engelmt@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Engelman</last_name>
      <phone>216-636-6153</phone>
      <email>engelmt@ccf.org</email>
    </contact>
    <investigator>
      <last_name>W. H. Wilson Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanley L. Hazen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922.</citation>
    <PMID>21475195</PMID>
  </reference>
  <reference>
    <citation>Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013 May;19(5):576-85. doi: 10.1038/nm.3145. Epub 2013 Apr 7.</citation>
    <PMID>23563705</PMID>
  </reference>
  <reference>
    <citation>Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT. Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women. Eur J Clin Nutr. 2008 Mar;62(3):386-94. Epub 2007 Mar 21.</citation>
    <PMID>17375117</PMID>
  </reference>
  <reference>
    <citation>Bidulescu A, Chambless LE, Siega-Riz AM, Zeisel SH, Heiss G. Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. BMC Cardiovasc Disord. 2007 Jul 13;7:20.</citation>
    <PMID>17629908</PMID>
  </reference>
  <reference>
    <citation>Tang WH, Wang Z., Levison B, et al., Gut Flora-Generated Metabolite of Phosphatidylcholine and Incident Major Adverse Cardiac Risks. N Engl J Med 2013; 468(17): 1575-84.</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Wilson Tang</investigator_full_name>
    <investigator_title>Staff Cellular and Molecular Medicine and Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>TMAO</keyword>
  <keyword>Gut Flora</keyword>
  <keyword>Dietary Intervention</keyword>
  <keyword>Choline</keyword>
  <keyword>Carnitine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

